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(EUSOBI), with language review by Europa Donna–The European Breast Cancer CoalitionAbstract
We summarise here the information to be provided to women and referring physicians about percutaneous breast
biopsy and lesion localisation under imaging guidance. After explaining why a preoperative diagnosis with a
percutaneous biopsy is preferred to surgical biopsy, we illustrate the criteria used by radiologists for choosing the most
appropriate combination of device type for sampling and imaging technique for guidance. Then, we describe the
commonly used devices, from fine-needle sampling to tissue biopsy with larger needles, namely core needle biopsy and
vacuum-assisted biopsy, and how mammography, digital breast tomosynthesis, ultrasound, or magnetic resonance imaging
work for targeting the lesion for sampling or localisation. The differences among the techniques available for localisation
(carbon marking, metallic wire, radiotracer injection, radioactive seed, and magnetic seed localisation) are illustrated. Type and
rate of possible complications are described and the issue of concomitant antiplatelet or anticoagulant therapy is also
addressed. The importance of pathological-radiological correlation is highlighted: when evaluating the results of any
needle sampling, the radiologist must check the concordance between the cytology/pathology report of the sample and
the radiological appearance of the biopsied lesion. We recommend that special attention is paid to a proper and tactful
approach when communicating to the woman the need for tissue sampling as well as the possibility of cancer diagnosis,
repeat tissue sampling, and or even surgery when tissue sampling shows a lesion with uncertain malignant potential (also
referred to as “high-risk” or B3 lesions). Finally, seven frequently asked questions are answered.
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 Image-guided needle biopsy is a safe and accurate
non-surgical method to diagnose suspicious
abnormal findings at breast imaging, pivotal for
adequate decision-making, including treatment
planning.
 Complete and adequate information must be given
to the woman before image-guided breast
interventions and informed consent should be
obtained from the woman before the procedure.
 The combination of device for sampling and image
modality for guidance is chosen by the radiologist
for each individual case.
 Pathological-radiological correlation, i.e., the check
of concordance between cytology/pathology report
of the sample and radiological appearance of the
lesion, must be performed.
 Image-guided preoperative localisation is mandatory
for guiding surgery of nonpalpable lesions or
surgically relevant extension of palpable lesions.
Introduction
Percutaneous image-guided needle biopsy is essential in
the management of suspicious breast lesions detected by
screening or during the assessment of clinical abnormal-
ities. It is a safe and cost-effective procedure allowing for
an accurate diagnosis, pivotal for adequate decision-
making, including, when indicated, treatment planning.
Percutaneous image-guided breast biopsies have almost
entirely replaced diagnostic surgical excisions that were
associated with longer hospital stay, higher cost, and
possible complications. In 2010, the European Society of
Breast Cancer Specialists, EUSOMA, suggested that 90%
of all the women with breast cancer (invasive or ductal
carcinoma in situ [DCIS]) should have a preoperative
diagnosis by means of percutaneous biopsy [1].
Moreover, the increasing rate of nonpalpable breast le-
sions detected in screening programmes as well as the
general goal of reducing the extent of surgical treatment
have increased the need for localisation before surgery.
Localisation can also be performed when neoadjuvant
therapy is under consideration in order to mark the le-
sion site for re-evaluation and treatment planning. It is
routinely performed using same image guidance tech-
niques used for biopsy and allows for conservative surgi-
cal excision of a limited amount of tissue, yielding
together an effective treatment and good aesthetic re-
sults [2, 3].
Different modalities are available for image-guided
breast biopsy and localisation procedures, each of them
with their own strengths and weaknesses [4–6]. The
most appropriate method is chosen by radiologists for
each individual case. Breast radiologists covering the fullspectrum of breast imaging and percutaneous tissue
sampling techniques (including the use of markers) and
presurgical localisation methods are the most suitable
professionals for choosing the optimal technique. When
localising methods imply the use of radiotracers or
radioactive seeds, radiopharmacy and radio safety train-
ing (or cooperation with nuclear medicine/radiotherapy
departments) is needed.
This article is the fifth of a series of recommendations
for women’s information, all issued by the European
Society of Breast Imaging, EUSOBI, the first [7] and the
third [8] focusing on mammography, the second on
breast magnetic resonance imaging (MRI) [9], and the
fourth on breast ultrasound (US) [10]. The current art-
icle represents also an update of a previous EUSOBI
guideline regarding diagnostic interventional breast
procedures, published in 2007 [11]. It is in particular
addressed to patients for whom an image-guided breast
biopsy or localisation is, or may be, under consideration
and to physicians dealing with these patients. In particu-
lar, eight special information notes (from A to H) and
seven frequently asked questions (FAQs) are formulated
for direct communication with women. Considering the
differences across European countries in terms of avail-
able technology, national guidelines, clinical practices,
health care systems, and insurance coverage, the applica-
tions of these recommendations can vary under local
conditions.
A search on the PubMed/Medline has been performed
for papers published from January 2009 to March 2019,
using the terms “breast” AND “biopsy” OR “fine needle”
OR “localization” OR “marker” OR “interventional”. Arti-
cles with an informative content most suitable for the
purpose of these recommendations were selected as refer-
ences with special regard to predetermined issues: safety/
quality, protocols and techniques, test performance (sensi-
tivity and specificity), and clinical indications. Other arti-
cles were included when found to be important among
the references of the retrieved articles or when suggested
by one or more authors. The entire text underwent a
double evaluation by the authors, each of them contribut-
ing with relevant intellectual content. However, as many
different topics are considered, single authors generally
agreeing on these recommendations may have different
opinions on individual statements.
This article summarises the information to be provided
to women and referring physicians about percutaneous
breast biopsy and presurgical localisation under the guid-
ance of mammography/tomosynthesis, US, and MRI.
Why is preoperative diagnosis through a
percutaneous biopsy preferred to surgical biopsy?
Currently, even taking into account recent advances in
breast imaging, tissue sampling represents the most
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nancy [4]. In fact, there are a variety of benign abnor-
malities which can mimic malignancy on all breast
imaging modalities, i.e., mammography and other x-ray
techniques (including tomosynthesis and contrast-
enhanced mammography), US, and MRI. The reason to
perform a percutaneous biopsy is to prevent unnecessary
surgery, associated morbity and costs for equivocal find-
ings on imaging with final non-malignant histopathology.
In addition, tailored treatment strategies are currently
available including chemotherapy and hormonal therapy
before or after surgery (so-called neoadjuvant therapy or
adjuvant therapy, respectively), surgical options from
lumpectomy to mastectomy with immediate reconstruc-
tion, whole or partial breast radiation therapy. The choice
among all these options is influenced not only by imaging
findings (especially in relation to disease extent) but also
by the diagnosis based on percutaneous tissue sampling,
in particular when the analysis includes not only basic
morphological characteristics but also the molecular
pattern of the tumour [11]. Moreover, needle sampling of
axillary lymph node, when indicated, adds information for
treatment planning [12–14].
We will describe here the details of the different tech-
nical options for breast tissue sampling—fine-needle
sampling (FNS), core needle biopsy (CNB), and vacuum-
assisted biopsy (VAB)—and the imaging modalities for
guidance.
We highlight the results of the latest systematic review
of the literature and meta-analysis, published in 2014 by
the United States Agency for Healthcare Research and
Quality [15]. Based on 160 studies using CNB and VAB
techniques, the authors found that both US-guided and
mammography-guided biopsies had average sensitivities
over 97% and specificities ranging from 92 to 99% while
non-imaging-guided free-hand biopsy methods had an
average sensitivity of 91% and specificity of 98%. Consider-
ing that free-hand non-imaging-guided biopsies are per-
formed only on large palpable lesions, image-guided
biopsies had better results for the more demanding task of
sampling nonpalpable, smaller lesions. For this reason,
free-hand breast biopsy cannot be recommended whenever
image-guided biopsy is available. CNB and VAB devices
(under the same imaging guidance) had similar perfor-
mances; CNB was found to be associated with a lower risk
of adverse events and complications than open surgical bi-
opsy, which were sparsely reported (e.g., 2–10% haemato-
mas, 4% repeat biopsy, 4–6% infections, 2% abscesses).
The incidence of adverse events with CNB was found to
be 1–1.5% and that of severe complications less than 1%
for all needle sampling techniques; VAB appeared to be
associated with increased bleeding and haematoma forma-
tion; biopsies performed with patients seated upright ap-
peared to be associated with increased risk of vasovagalreactions; CNB obviated the need for surgery procedures
in about 75% of women. The authors concluded that the
evidence suggests that US-guided and mammography-
guided biopsies have sensitivity and specificity close to that
of surgical biopsy with fewer adverse events and that non-
imaging-guided free-hand procedures have lower sensitivity
than image-guided methods. This large literature review
clearly explained the reasons for recommending image-
guided biopsy instead of surgical biopsy as a general rule
of good practice. However, with regard to VAB versus
CNB, lesion size and type must be considered and this
may have resulted in an underestimation of the potential
advantages of VAB over CNB, particularly when using
mammography, tomosynthesis, or MRI guidance.
It is important to note that percutaneous needle bi-
opsy may not provide a definitive diagnosis when the
histopathological report describes the presence of a
lesion with uncertain malignant potential (also called
high-risk or B3 lesion). This occurs in 3 to 9% of cases,
with a range of rates turning out to be malignant (10–
33% or also higher rates) [10, 16–25]. These lesions in-
clude atypical ductal hyperplasia, benign phyllodes tu-
mours, flat epithelial atypia, classical lobular neoplasia,
papillary lesions, radial scars, and other rare entities.
Each of them, when surgically removed, shows a variable
upgrade rate to invasive cancer or DCIS [26]. Although
a small but significant increase of imaging surveillance
has been described for classical lobular neoplasia, flat
epithelial atypia, and papillary lesions diagnosed on
VAB instead of surgical removal, from 24 to 35% of
high-risk/B3 lesions (in particular, atypical ductal
hyperplasia and phyllodes tumours), are recommended
for surgery [27]. In addition, breast specialists should
take into account that women diagnosed with high-
risk/B3 lesions have a long-term moderately increased
risk of breast cancer [28].
Women should be informed that the radiologist may
propose a repeat needle sampling or surgical interven-
tion also in the case of biopsy resulting into normal
breast tissues or benign abnormalities. After a negative
breast tissue needle sampling, imaging follow-up is usu-
ally planned, with imaging modalities and time interval
to be defined for each individual case.
Note A. Percutaneous image-guided biopsy has
replaced surgical biopsy allowing a minimally invasive
safe, accurate, and cost-effective diagnosis of breast
lesions, necessary for the definition of treatment
planning. In the case of a biopsy resulting in a
pathological diagnosis of a high-risk/B3 lesion, discuss
with your radiologist and the breast care team the best
option for you (either repeat biopsy, surgical removal,
or imaging surveillance). After a negative image-
guided tissue sampling, imaging follow-up is usually
Ta
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be defined for each individual case.Options for breast tissue sampling: from thin to
thick needles
Different percutaneous image-guided techniques are
available to diagnose palpable and nonpalpable breast le-
sions. In the last decades, they have improved patient
management, avoiding unnecessary surgical biopsy for
benign lesions [29]. Nowadays, FNS, CNB, and VAB
coexist, the first providing material for studying cells
(cytological examination), the last two providing material
for studying tissues (histopathological examination). All
these techniques can be theoretically guided by mam-
mography, tomosynthesis, US, or MRI. However, FNS
and CNB should be used under US guidance, VAB
under mammography/tomosynthesis or MRI guidance.
These prevalent combinations are due to both technical
considerations, including visibility at each technique and
lesion types detected. Breast size, lesion location and size
as well as local availability of instrumentation and ex-
pertise are taken into account. Table 1 shows the indica-
tions for the combinations between imaging guidance
and sampling type.
Whenever the lesion is well identified on US, this tech-
nique is preferred due to the easy approach and the short
duration of the procedure (implying a more comfortable
woman’s experience) as well as a lower cost. If a lesion is
not clearly identifiable on US, mammography, tomo-
synthesis or MRI is used for guidance, typically the
former in the case of suspicious calcifications and archi-
tectural distortions and the latter in the case of lesions
only visible on MRI [30].
Needles of different size and length are adopted for
percutaneous image-guided biopsies. The diameter is de-
scribed by gauge numbers. Differently from an intuitive
reasoning, smaller gauge numbers indicate larger needle
diameters. Commonly applied needles have a diameter
ranging from 0.4 (27 gauge) to almost 4.6 mm (7 gauge).
Fine-needle sampling
As mentioned before, FNS is performed almost only
under US guidance. Local anaesthesia can be performed
but it is not ubiquitous practice. A fine needle with
diameter variable from 27 to 18 gauge (same or similarble 1 Current options for breast tissue sampling: combinations of
age guidance/sampling type Fine needle
rasound Conditionally indicateda
mmography/tomosynthesis Not indicated
I Not indicated
ne-needle sampling has specific limitations; it is reliably used by centres having sto those used for intramuscular injections) is inserted
very close to the US probe and, once the needle is seen
inside the target, a manual multidirectional sampling is
performed, through aspiration using a 10-20-mL syringe
or a vacuum aspiration system (fine-needle aspiration)
or simply by manual movement of the needle inside the
lesion (fine-needle capillary sampling) for about 10–20
sec. The extracted material is then spread onto slides
and placed in formalin for cytological analysis. The pro-
cedure is easy, safe, and fast to perform and the associ-
ated cost is very low. When the cytopathologist is onsite
during the sampling, results may be available very soon
after the procedure [31]. The success of the technique is
highly dependent on the skills of the physician perform-
ing the sampling and of the cytopathologist interpreting
the sample as well on their interplay [32]. A meta-
analysis published in 2008 [33] reported on 25 studies
describing FNS cytology analyses performed from 1984
to 2007 on palpable breast masses. The pooled sensitiv-
ity was 93% (range 78–100%) and the pooled specificity
98% (range 76–100%). A significant increase in diagnos-
tic performance was shown during the years and attrib-
uted to technologic improvements. However, we should
note that the report considered only FNS performed on
palpable, i.e., relatively large, masses.
It is not surprising that higher rates of inadequate or
false-negative results and lower accuracy rates have been
reported for FNS compared to CNB. In fact, relying only
on cells, FNS cytology cannot always reliably distinguish
between benign tissues, high-risk/B3 lesions, DCIS, and
invasive malignant changes. In many centres, the informa-
tion about tumour biomarker status (especially required
when a neoadjuvant treatment is under consideration)
cannot be obtained from FNS [11]. For these reasons, FNS
has increasingly been replaced by CNB or VAB in the
diagnosis of breast lesions [34, 35]. As already said, FNS
cytology reliability must be considered strongly depending
on local factors, i.e., on the experience of operators as well
as the presence of a cytopathologist in the room during
the procedure. When its performance is high, it can be
used as the first fast approach, using CNB or VAB as sec-
ond step, when needed.
US-guided fine-needle aspiration is widely accepted for
draining complicated cysts (e.g., cysts with internal deb-
ris), seromas or haematomas, for therapeutic purposes
for pain relief from swelling cysts, or in the case ofneedle types and imaging guidance
Core needle Vacuum-assisted
Indicated Indicated
Not indicated Indicated
Not indicated Indicated
pecific local experience (see text)
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scesses, as an effective alternative to surgery [36–39]. In
particular, lactational abscesses can be managed by US-
guided percutaneous treatment, avoiding surgery even for
abscesses greater than 5 cm and allowing continued breast-
feeding [38]. In the case of complex cysts (thick-walled cys-
tic lesions with or without thick internal septations,
intracystic solid masses, and mixed cystic/solid lesions),
CNB is preferred [36].
Core needle biopsy
Ultrasound guidance is the most commonly used ap-
proach for CNB. After local anaesthesia is administered
through subcutaneous injections of drugs similar to
those used by dentists (e.g., lidocaine), a needle with a
size usually varying from 16 to 12 gauge (most com-
monly 14 gauge), is inserted by the radiologist, often
through a small skin incision. Once the needle is con-
firmed to be on target, a tissue sample (core) is obtained
with a needle of variable length (from about 10 to over
20 mm), depending on the used device, and immediately
fixed in small formalin containing jars. Since a lesion
may be pushed ahead while shooting, the longer samples
obtained from longer acquisition chambers are usually
preferred. Biopsy devices utilise a spring-loaded needle
(or “gun”) that are semiautomatically or automatically
fired into the lesion. This fire is accompanied by a noise
and the patient should be informed of this to avoid
movements during the biopsy. A variable number of
cores (usually 3–5) are obtained through subsequent
samples and needle extractions. Images are acquired
to document the correct needle positioning [40–42].
CNB yields material that can be histologically evalu-
ated; it allows a high rate of adequate sampling and a
low false-negative rate; in addition, it allows obtaining
biological markers necessary for treatment planning.
In the case of US-guided 14-gauge CNB, the false-
negative rate has been reported to range from 1.2 to
3.3% (mean 2%) [43].
However, since only a portion is sampled from het-
erogeneous tissue, the risk of pathological underesti-
mation remains. This term means that the needle biopsy
may provide a result different from that obtained after
surgical removal, typically high-risk/B3 lesion instead of
DCIS or invasive cancer, or DCIS instead of invasive
cancer.
In 2% of cases [43] CNB may provide a false-negative
diagnosis, although this event is less frequent than with
FNS. Reasons for false negatives can be errors in lesion
targeting (bleeding or lesion movement when the needle
is fired), histological malignant/benign heterogeneity of
lesion (the samples only contain benign tissues, even
though the needle was correctly placed). The latter may
occur with lesions with heterogeneous texture or indiffusely growing malignancies, where only single cells
or nests of cells are contained in otherwise benign
appearing or fibrotic tissue (e.g., DCIS, lobular invasive
cancers, diffusely growing invasive ductal cancers).
The most important step to avoid false-negative results
after percutaneous breast biopsy is systematic radiologic-
pathologic correlation of all benign and high-risk/B3
histopathological results by the multidisciplinary team
including the pathologist and the radiologist.
Depending on the underlying histological abnormality,
from 10 to 50% of lesions characterised as high-risk/B3 (i.e.,
lesions with uncertain malignant potential) biopsied using
CNB will eventually turn out to be malignant [24], and
around 25% of tumours diagnosed as DCIS using CNB will
have an invasive component on final surgery [44].
Vacuum-assisted biopsy
This method uses needles with a size from 12 to 7 gauge,
the latter being the largest size commercially available
for a percutaneous breast biopsy. After local anaesthesia,
through a small incision in the skin, a special needle
connected to a vacuum-generating device is inserted into
the breast and number of tissue samples are taken. Mul-
tiple samples can be taken sequentially without removing
the needle, which is different to CNB. In addition, the
vacuum attracts the tissue towards the needle and a ro-
tating device cuts the samples. This approach allows for
rapid removal of much larger amounts of tissue in com-
parison to CNB, i.e., 1 g or 1 cm3 of tissue per procedure
or more [45, 46], thus reducing (but not nulling) the risk
of false-negative results or pathological underestimation
[47]. Since blood is suctioned from the biopsy site, the
risk of lesion displacement by bleeding is reduced.
The VAB can be performed under mammography, tomo-
synthesis, US, or MRI guidance. The use of VAB is crucial
for findings such as microcalcifications or architectural tis-
sue distortions on mammography or tomosynthesis as well
as for suspicious contrast-enhancing lesions on MRI that
cannot be found with other methods [48]. With aspiration
and rinsing of the cavity, VAB has been established as an
appropriate and effective technique for US-guided percu-
taneous drainage of breast abscesses [38, 39].
When VAB is performed under US guidance, the pa-
tient is positioned in the same way as diagnostic exami-
nations, i.e., in a supine position; for MRI-guided VAB,
the patient is positioned in prone position. When mam-
mography/tomosynthesis is used for guiding the proced-
ure, both dedicated horizontal tables (with the patient in
prone position) or upright systems (with the patient
seated or laying on her side on a special table or chair)
are available, according to experience and resources of
the medical centre, both of them being suitable. Dedi-
cated prone tables are more expensive than the upright
alternatives but are less frequently associated with
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ring below the table cannot be seen by the patient.
For mammography- or MRI-guided procedures, once
the lesion has been localised on images, a computer de-
termines the spatial coordinates that define the lesion
position. After local anaesthesia is administered, the nee-
dle is positioned in place. If an US-guided VAB is used,
real-time scanning is used to identify the lesion and to
reach the target; in the case of mammography or MRI
guidance, images are acquired to document the needle
position [48]. Multiple (up to 12 or more) tissue cores
through a 9-gauge or 12-gauge needle are obtained, or a
comparable volume with other needle sizes [47]. A rela-
tively large amount of tissue is required for an accurate
histopathological analysis. Small lesions (e.g., less than 1
cm in size) may be completely removed.
Other breast biopsy systems
In the last decade, percutaneous image-guided systems
aiming to completely remove small breast lesions have
been developed [49–51], for instance using radiofre-
quency to excise intact lesions in a basket preserving the
tissue structure [52–55]. These devices have the poten-
tial to provide highly accurate tissue diagnosis and offer
an alternative option for percutaneous lesion removal.
However, they are currently mainly used in the context
of research studies.
Post-biopsy marker deployment
A marker, typically a metallic clip visible on mammo-
grams (but also markers visible on US and/or MRI), can
be placed in the biopsy site at the end of sampling with
CNB or VAB to allow for subsequent checking of con-
cordance between the pathological results and imaging
appearance, as well as for preoperative localisation. This
is especially important for small lesions that can be com-
pletely removed with VAB and are no longer visible after
biopsy [56] and also for completely drained cystic le-
sions. Positioning a marker is also necessary to mark le-
sions in patients who are candidates for neoadjuvant
therapy. In the case of important tumour regression,
when lesions may no longer be visible on imaging, the
clip indicates the tumour location and can be targeted to
excise the tumour bed. A marker is always placed after
an MRI-guided biopsy, even if the lesion remains visible
after biopsy. This confirms the correct location of the
sampling but also allows performance of any subsequent
intervention by means of the easier mammographic or
US guidance.
For biopsies with marker placement, a post-biopsy
mammogram is commonly performed, either immedi-
ately following the procedure or later, e.g., at the time
when the biopsy results are discussed. This mammo-
gram is useful for confirming lesion targeting (correct ordisplaced location of the marker in the biopsy site) and
assessing reduction or absence of lesion findings (e.g.,
calcifications) after biopsy. In addition, it provides a
comparison for future follow-up exams.
Note B. When a breast abnormality identified on
imaging requires a tissue diagnosis, different biopsy
options exist to obtain adequate samples. Among FNS,
CNB, and VAB, the radiologist will opt for the best
method allowing for an accurate diagnosis, depending
on lesion appearance, patient characteristics, and local
availability of devices. When needed, a metallic
marker at the biopsy site is placed. Don’t worry: these
markers are not a contraindication for any MRI
examination and do not alarm at the airport!Choosing the optimal imaging guidance
Image guidance outperforms non-imaging-guided free-
hand approaches for breast lesion sampling. The choice
among mammography/tomosynthesis, US, or MRI
methods is made by the radiologist according to several
factors, the most important being the visibility of the le-
sion to be targeted.
US guidance
If a lesion is visible on US, the best choice is to perform
the biopsy under its guidance [57, 58]. US is readily
available, does not expose the patient to ionising radi-
ation, and allows for real-time checking of needle place-
ment. US-guided biopsy can also be performed as a
bedside procedure in bed-bound patients and there are
virtually no contraindications or anatomical/technical
restrictions for biopsy access to breast lesions. Typically,
US-guided biopsy is performed as CNB, allowing for a
safe, fast, effective, and cheap procedure [42, 57], but US
is also suited to guide FNS or VAB, taking into account
that each system can have specific characteristics [58].
During US-guided biopsy, the patient is usually posi-
tioned supine or in the supine oblique position, similar
to the US examination (depending on the location of the
lesion) (Fig. 1). The duration of a US-guided procedure
is about 5 to 15 min, mainly depending on the type of
needle used, number of samplings, lesion site, and radi-
ologist’s experience.
Mammographic guidance
Mammographic guidance is the method of choice for le-
sions detected by mammography which do not have a clear
correlate on US [51]. Most of these lesions are suspicious
calcifications, architectural distortions, or small masses.
The well-established method for mammography-guided bi-
opsy is called stereotaxis, a term that refers to the need of
two oblique projections providing a two-view (stereo)
Fig. 1 Ultrasound-guided core needle biopsy. The patient is in
supine position. After local anaesthesia, the ultrasound probe (on
the left) guides the needle to the lesion
Fig. 3 Mammography-guided (stereotactic) vacuum-assisted biopsy.
The patient is sitting on a dedicated chair. After local anaesthesia,
the needle is guided to the lesion by the computer on the basis of
specifically acquired mammographic images
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tions are performed using dedicated prone tables, where
the biopsy equipment is located below the patient, thus not
visible to the patient during the procedure (Fig. 2), or up-
right mammographic add-on systems, with the patient
usually sitting (Fig. 3) or lying in lateral decubitus during
the procedure. A mild compression is required for breast
immobilisation.
With dedicated prone systems, vasovagal reactions can be
easily managed, but the upright add-on systems allow inter-
ventions to be performed in women who cannot lie prone
due to orthopaedic problems. All stereotactic biopsies
performed for calcifications should be followed by speci-
men radiography to document adequate sampling, i.e.,, the
presence of calcifications within the samples. The duration
of an uncomplicated stereotactic biopsy itself, excluding
patient information before and after the procedure, histo-
pathological correlation and reporting as well as prepar-
ation and cleaning of the room, is about 30 min.
In the last few years, mammography guidance can also
be performed using digital tomosynthesis, a techniqueFig. 2 Mammography-guided (stereotactic) vacuum-assisted biopsy.
The patient is in prone position lying on the table over the field of
view of the image, with the breast pendent by gravity (she does not
see the procedure). After local anaesthesia, the needle is guided to
the lesion by the computer on the basis of specifically acquired
mammographic imagesthat provides images of thin slices of the breast [8, 62, 63].
These systems allow for precise localisation of the target
with reduced time and radiation exposure compared to
conventional stereotactic biopsy under mammographic
guidance [64, 65]. The duration of a tomosynthesis-guided
biopsy is about 10–15min.
MRI guidance
MRI-guided VAB is a safe and accurate procedure that is
mandatory when suspicious lesions are visible on MRI
only [48, 66–68]. Of note, among MRI-detected lesions,
46 to 71% may be revealed by a subsequent targeted US
(the so-called targeted US or second-look US), even if
breast US performed before MRI did not detect any ab-
normalities [69–71]. Importantly, identifying an MRI-
detected lesion on US allows the biopsy to be performed
under US guidance, in an easy, fast, comfortable, and
cheap way [10]. Thus, the need for MRI-guided proce-
dures is relatively limited: even large tertiary breast care
institutions account for less than five patients per month
[48]. It has been suggested that a high number of speci-
mens may decrease underestimation rates of MRI-guided
vacuum-assisted biopsy [72]. A large European multicen-
tre study on MRI-guided biopsy of 538 lesions [73] re-
ported a success rate of 96%, without any false negative
among the 517 successful procedures at a median follow-
up of 32months (range 24–48months).
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gadolinium-based contrast administration must be
checked as for any contrast-enhanced breast MRI [9],
taking into consideration any interval change (e.g.,
implantation of MRI-unsafe devices) between the pre-
vious breast MRI exam and the current MRI-guided
procedure to be performed.
It is important to note that devices and software for
MRI-guided interventions are not ubiquitously available
across countries, and women cannot easily access these
procedures partly due to diversity in public/insurance
coverage and reimbursement policy. A EUSOBI survey
among European radiologists [74] showed that only
about one third of 177 responders practice MRI-guided
interventions.
MRI-guided biopsy is performed on the MRI table,
with a sequence of movements inside and outside the
magnet. The patient is placed in prone position with the
targeted breast gently compressed in a dedicated biopsy
grid (Fig. 4). A dedicated radiofrequency coil is required
to enable image acquisition and to guide needle place-
ment. The procedure is safe and accurate in specialised
centres and relatively fast, but longer if compared to
other imaging-guided procedures. Notably, there may beFig. 4 Magnetic resonance imaging-guided vacuum-assisted biopsy.
The patient is prone, positioned on a dedicated coil that allows to
insert the needle through a greed (light blue arrow), shown in the
figure outside the magnet. After local anaesthesia, the needle is
guided to the lesion on the basis of specifically acquired magnetic
resonance images. To conclude the procedure, the patient has to
enter and exit the magnet at least three times (see text)limited access for lesions close to the chest wall (de-
pending on the biopsy coil setup) or close to the nipple
as well as for lesions in small breasts. An MRI-guided bi-
opsy is a multistep procedure and may exceed 30-min
magnet time, considering the following steps:
1) The patient is placed inside the magnet.
2) Pre-contrast and immediate post-contrast T1-
weighed series are acquired for lesion localisation.
3) The patient is moved out of the magnet to
percutaneously access the lesion (from the side).
4) The patient is again moved inside the magnet for
checking the biopsy device position.
5) The patient is moved out of the magnet to perform
the biopsy and deploying the marker.
6) The patient is then finally moved inside the magnet
to evaluate marker localisation and possible
complications such as bleeding
Of note, additional time is needed for compressing the
breast after biopsy (especially if bleeding occurs) and for
cleaning, before the next patient can be examined.
Note C. If a suspicious lesion is visible on US, the best
choice is to perform the biopsy under US guidance. If a
suspicious lesion is visible only on mammography or
tomosynthesis, these methods have to be used for
guiding the biopsy. If a suspicious lesion is visible only
on MRI, MRI-guided biopsy should be performed; if
your centre has no possibility to perform an MRI-
guided biopsy, ask your radiologist for a referral to a
centre offering this procedure.Axillary lymph node needle biopsy
Axillary lymph node assessment is an integral part of
preoperative staging in patients with newly diagnosed in-
vasive breast cancer [12]. Information about possible
metastatic involvement of axillary lymph nodes can help
avoid unnecessary procedures, triaging patients directly
to axillary lymph node dissection [13]. Axillary lymph
node US is the easiest way to identify abnormal lymph
nodes. Tissue sampling with FNS or CNB is similar as in
the breast. CNB seems to be more accurate than FNS in
the diagnosis of axillary lymph node metastasis [14]. The
incidence of adverse events is rather low; however, com-
plications can be more severe than those of breast tissue
sampling. After a biopsy, a clip may be placed in the bi-
opsied lymph node, and marking of lymph nodes with
clips and other devices is currently under investigation.
Pathological-radiological correlation
For any combination of guidance methods and needle
types, concordance between the cytological or pathological
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has to be verified. This mandatory task must be performed
by the professional who performed the image-guided
sampling, usually a breast radiologist, in collaboration with
the reporting pathologist [75–78].
In most cases, the radiologist will consider the cytology
or pathology result as concordant with imaging findings,
especially when CNB or VAB has been performed. How-
ever, in the case of inadequate sampling (more frequent in
the case of FNS) or discordance between cytology/path-
ology and imaging findings, a repeat biopsy using the
same or a different biopsy method can be considered,
which is often after discussion in the multidisciplinary
meeting. In the case of findings highly suspicious for
malignancy on US, mammography/tomosynthesis, or MRI
with discordant benign findings at FNS/CNB/VAB, it is
also possible to go directly for surgical removal, after
preoperative image-guided localisation, if the lesion is
nonpalpable.
Possible side effects and complications including
neoplastic seeding
Percutaneous breast biopsies are minimally invasive and
in general very safe, with severe complications requiring
treatment being exceedingly rare [15, 34]. Common side
effects include minor pain and bruising [41]; other com-
plications are large haematomas or infections, at a rate
of one every 1000 procedures [77, 79].
The risk of bleeding will increase with the needle
diameter and the amount of sampled tissue [15]. Bleed-
ing after biopsy is usually self-limited or limited by man-
ual compression for 5–10 min (the time may be longer
in the case of arterial bleeding) but may produce mild
discomfort and pain for several days. Severe bleeding re-
quiring surgical intervention is very rare. Careful screen-
ing for bleeding disorders, avoidance of vessels when
choosing the needle track (possible only under US guid-
ance using colour-Doppler imaging), and adequate com-
pression after the procedure reduce the probability of
severe bleeding.
Pseudoaneurysm (also called false aneurysm) of breast
vessels is a very rare complication after either CNB or
VAB, reported in the literature mainly as case reports. It
is due to blood leaking from a breach in the arterial wall,
contained by the adventitia or surrounding perivascular
soft tissue. An enlarging mass a few days after the proced-
ure, showing blood flow inside, is the commonest presenta-
tion. Management options include observation, US-guided
focused compression, thrombin injection, open surgical re-
pair, and percutaneous embolisation [80].
As with any percutaneous intervention, a low risk of
infection does exist, so using sterile packed devices and
keeping the environment clean as much as possible is
important. The risk of infection after breast biopsies isextremely rare, reported to be 0.1% for US-guided biop-
sies [81]. They are mostly limited to skin or soft tissue
and highly responsive to oral antibiotics. The risk of
infection may be higher in patients with diabetes or a
compromised immune system.
The risk of mechanical displacement of malignant cells
along the biopsy tract can very rarely occur and is
referred to as neoplastic seeding. The incidence of this
event was reported to be 2 of 1644 biopsies [82] or,
more recently, 8 of 4010 biopsies, [83], meaning that
one or two of such events are expected every one thou-
sand biopsies, likely because the displaced tumour cells
are usually not viable [84]. Their biological significance
is disputed, since such seeding is mostly located in the
skin and detected early and thus removed without con-
sequences. A retrospective analysis [85] including 719
patients after conserving surgery and radiotherapy for
stage I and II breast cancer (189 patients having pre-
operative CNB and 530 without, with a median follow-
up of 78 and 71 months, respectively) did not show
increase of the local recurrence rate for the CNB group.
A study [86] reported an increase in distant metastases
at long-term follow-up for a cohort of patients who
underwent CNB versus FNS. However, the study has
relevant limitations, the most important being the retro-
spective design, the small sample size and the times of
cancer diagnosis of the two cohorts (203 patients diag-
nosed from 1991 to 1995 for CNB; 181 patients diag-
nosed from 1971 to 1976 for FNS). The authors adjusted
for the difference in treatment over time. However, the
20-year time difference implies a greater sensitivity for
metastases in the CNB cohort as a non-negligible source
of bias [87]. In addition, no prospective studies repli-
cated these findings.
A severe, but extremely rare complication of a free-
hand or US-guided breast biopsy is the development
of a chest wall injury, for example a pneumothorax,
especially if an inexperienced examiner uses an im-
properly steep angle for access [88]. A pneumothorax
is an abnormal collection of air between the lung and
the chest wall and presents with sudden onset of
sharp, one-sided chest pain and shortness of breath.
The risk is practically null with mammography or
MRI-guided biopsy, because the needle is introduced
parallel to the chest wall.
Note D. Percutaneous breast biopsy is a safe
procedure, with an extremely low risk of serious
complications needing surgery or emergency
assistance. Mild complications are also very rare: a
certain degree of bleeding is the most common
side-effect, usually self-limited; skin or soft-breast
tissue infections respond well to oral antibiotics.
The probability of neoplastic seeding along the
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sidered irrelevant due to the adjuvant radiation
and pharmacological treatment in case of breast
cancer. All mentioned complications are less frequent
than complications under surgical biopsy with or
without full anaesthesia.1Rules for the informed consent required for needle tissue sampling
and lesion localisation can be different according to national, regional,
or local regulations, including written informed consent after
presentation of written information about advantages and
disadvantages associated to the procedure or oral informed consent
described in the radiological report.Preparation for image-guided breast
interventions
The planned procedure, including the rationale for per-
forming the biopsy/localisation, potential benefits, possible
complications, and likely outcomes must be explained in
detail to the patient and informed consent should be ob-
tained in advance (e.g., when planning the procedure or 1
−2 days before the procedure) or immediately before the
procedure [51, 58].
Bleeding disorders and antiplatelet and anticoagulation
therapies
To minimise the risk of bleeding, patients scheduled for
percutaneous breast biopsy should be screened for bleeding
disorders and antiplatelet and anticoagulation therapy. For
CNB, blood tests are considered necessary only in the case
of a personal or family history of anticoagulation therapy.
For VAB, most institutions prefer having blood testing per-
formed, but in the absence of positive history, to perform
the procedure without blood testing is considered accept-
able. Breast biopsy is considered a percutaneous procedure
with low risk of bleeding. If necessary, breast biopsies can
safely be performed even in patients receiving anticoagula-
tion treatment [41, 89]. Depending on national or local rec-
ommendations, anticoagulant agents like warfarin may be
discontinued some days before and resumed 12 h after the
procedure. For patients who cannot be off anticoagulation
therapy, heparin bridge therapy may be planned by the
clinical team. Low-dose or high-dose acetylsalicylic
acid (aspirin) treatment does not need to be blocked
while clopidogrel may be discontinued some days be-
fore and resumed immediately after the procedure
[90]. Specific recommendations are in use for newer
anticoagulant drugs. Of course, these recommendations
are more important for VAB than for CNB; in general,
the larger the needle and the higher the number of
planned samples, the more attention should be paid to
bleeding disorders and antiplatelet or anticoagulation
therapies. All decisions to discontinue therapies should
be taken in close collaboration with the prescribing
physician.
Pregnancy
In case of pregnancy, mammographic and MRI-guided
procedures are possible but the indications should be
adequately reviewed on a case-by-case basis.MRI-related contraindications
Patients planned for MRI-guided biopsy should undergo
the usual precautions including screening for MRI-
unsafe or MRI-conditional implants, prior reactions to
contrast agent administration, and renal function im-
pairment, as suggested by the EUSOBI recommenda-
tions for breast MRI [9].
The patients do not have to fast on the day of the pro-
cedure or discontinue other medications than those re-
lated to antiplatelet/anticoagulation therapy, as
explained above.
Note E. Informed consent is required before a breast
biopsy. Management of antiplatelet/anticoagulation
therapy may be adopted. Women should be informed
of possible adverse events and any allergies to local
anaesthetic drugs should be verified. If an MRI-guided
biopsy is planned, allergies to intravenous contrast
agents as well as contraindications to MRI should be
verified. Informed consent also includes communication
between the radiologist and the patient (see the next
paragraph).Patient’s experience and communication between
radiologist and patient
The patient should be informed about the reasons for per-
forming a needle biopsy or a localisation procedure.
Before the procedure, informed consent must be obtained
according to national/local regulations.1 Information must
be given on the devices (needles) used for sampling and for
guiding the sample, on the frequency of adverse events, side
effects, and complications, better if using natural frequencies
instead of percentages or complex epidemiological indices,
including the need for repeat biopsy or surgical excision in
cases of inadequate sampling, poor radiological-pathological
concordance, or pathological diagnosis of high-risk/B3 le-
sions, as explained above.
Patients should be informed about the possible neces-
sity of placing a marker clip in the biopsy site, taking
into account that some women may have objections
against potentially permanent placed foreign bodies in
their breasts. In those cases, precise information on the
risks associated with not using these markers has to be
provided to the patient, especially the risk of missing a
small lesion requiring surgery that may not be visible
after the biopsy.
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prior to the procedure, as the anticipated pain strongly
correlates with the level of pain experienced by the pa-
tient during the procedure, so that communication with
patients before biopsy regarding minimal average pain re-
ported during biopsy is a good strategy [91]. The quality
of human communication between the radiologist and the
patient has been demonstrated to impact on patient’s
anxiety [92]. A study reported that listening to guided
meditation lowered biopsy pain during biopsy and that
meditation and music reduced patient anxiety and fatigue
without a negative impact on radiologist-patient commu-
nication [93]. We highlight that a good organisation of the
medical team, a calm and efficient workflow, and a con-
stant communication with the patient before, during, and
after the procedure ensure a high compliance.
The experience of a patient needing a biopsy differs
according to the image guidance adopted, as explained
in the previous sections. While US-guided is in most
cases a straightforward and fast procedure lasting no
more than 15min, mammography/tomosynthesis- and
MRI-guided biopsies require preparatory technical mea-
sures aiming at the exact lesion localisation, leading to
procedural times that can exceed 30min and increase
patient anxiety. Some evidence exists that tomosynthesis
guidance can reduce the procedural time in comparison
with stereotactic guidance [64]; one study [65] compar-
ing 706 procedures under tomosynthesis guidance versus
439 procedures under stereotactic guidance showed an
over 50% reduction in procedural time and about 75%
reduction in radiation exposure.
Whichever combination of guidance and needle is used,
once the patient is positioned and the best and safest nee-
dle access route to the lesion has been chosen, the corre-
sponding skin is cleaned and disinfected. Whereas for
FNS the use of local anaesthesia is optional (the size of the
needle used is similar to an anaesthesia needle and the an-
aesthetic liquid could interfere with cytological aspiration),
all other types of percutaneous breast biopsy are usually
performed under local anaesthesia.
For superficial anaesthesia, lidocaine buffered in
sodium bicarbonate may be used to reduce the initial
stinging sensation of the lidocaine injection [41, 58]. In
the case of allergy to lidocaine, alternative drugs have to
be used. Even with optimal local anaesthesia, some dis-
comfort or pain may be felt during needle insertion and
tissue sampling, which will vary significantly from pa-
tient to patient [91].
At the completion of the biopsy, local manual com-
pression, usually for 5 min, as well as cooling, may be
applied to the biopsy site to achieve haemostasis and to
minimise the amount of bleeding. In addition, the appli-
cation of a compression bandage can be applied, in par-
ticular in the case of moderate or severe bleeding,Note F. Patients’ experience will be different
depending on the type of device used for sampling
and the imaging guidance adopted. A percutaneous
biopsy may last from 15 to 45 min and is generally
well tolerated. The position will be the same as
the diagnostic examination for US (supine) or
MRI-guided biopsy (prone) and may be prone,
seated, or in lateral decubitus for mammography/
tomosynthesis-guided biopsy, according to the
adopted system. Communication between the
radiologist and the patient is crucial for anxiety
reduction.Post-procedural recommendations and
communication of results
Following the biopsy procedure and after achieving
haemostasis with manual compression, wound cleaning,
and bandage, the patient is observed for 15–60 min in
the radiology suite, depending on the type of procedure
and the patient’s profile. Subsequently, she can be dis-
charged with appropriate instructions, including possible
pain and bleeding and corresponding remedies, ban of
water immersion (e.g., swimming) and strenuous exer-
cise for at least 3–5 days following the biopsy.
Whenever possible, biopsy results as well as recom-
mendations for further management (e.g., treatment or
follow-up) should be discussed with the patient in per-
son, usually during the visit after the biopsy. Timing of
this visit must strike a balance between minimising the
waiting time for the patient and its associated anxiety
and the necessity to allow for enough time to have path-
ology results including, if necessary, additional immune-
histological stains. In the cases requiring treatment, the
visit after the interventional procedure should include
the results from the multidisciplinary conference, at
which concordance of imaging and histological findings
is assessed and subsequent management is established.
Some centres have developed rapid diagnosis as
“one-stop breast clinics”, providing the results of the
biopsy immediately after the procedure. This type of
management has been proven to be cost-effective and
accurate [94]. However, efforts should be made to de-
crease distress and anxiety of the patients also in this
setting in regards to the quality of the patient-doctor
relationship and doctors’ interpersonal skills, doctors’
availability, and waiting time [95], which are important
general aspects to be improved in breast image-guided
interventions.
Note G. At the end of biopsy, the patient is
observed in the radiology department for 15–60
min. She can then be discharged and adequate
instructions on common side effects and
Ta
Me
Ca
Wi
Ra
Ra
Ma
Bick et al. Insights into Imaging           (2020) 11:12 Page 12 of 18complications, as well as corresponding remedies
are suggested. The next visit is planned for
communication and discussion of the results,
including the radiologist who performed the
procedure and participated in the assessment of
concordance between cytology/pathology diagnosis
and lesion appearance at breast imaging.Preoperative image-guided localisation of
nonpalpable breast lesions
Nonpalpable, clinically occult breast lesions amenable to
surgery need image-guided preoperative localisation.
This allows guidance of surgeons to the lesion for a safe
and effective intervention aiming at obtaining both a
complete removal (clear margins) and a good cosmetic
result [2, 3, 96]. Radiologists play a crucial role in this.
Different localisation methods currently exist and are
variably used in different institutions depending on per-
sonal choices, skills, and available technologies. The
image guidance adopted should be the easiest method
whereby the lesion (or the marker left after the biopsy)
can be identified with certainty. In case of findings only
visible on mammography/tomosynthesis (e.g., calcifica-
tions) or lesions revealed only on MRI, mammography/
tomosynthesis or MRI guidance have to be used, re-
spectively. This is why post-interventional marker place-
ment is encouraged: the marker allows a presurgical
localisation by US-guided marker identification. The
position of the patient is the same in which the biopsy
was performed; supine for US-guided methods; upright,
prone, or in lateral decubitus for mammography/tomo-
synthesis-guided methods; and prone for MRI-guided
methods.
Methods for preoperative localisation of nonpalpable
breast lesions are carbon marking, wire localisation, ra-
diotracer injection (usually called radio-guided occult le-
sion localisation, ROLL), radioactive seed localisation,
and magnetic seed localisation (Table 2).ble 2 Current options for image-guided localisation of nonpalpab
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resonanCarbon marking
Carbon marking is a long-standing method consisting of
injection of sterile charcoal powder diluted with saline
solution near to a nonpalpable breast lesion under US or
mammographic guidance, depending on how the biopsy
was performed [97, 98]. A dark trail is created from the
lesion to the skin leaving a visible spot. The surgeon is
guided by the presence of the carbon suspension, which
should be removed during the operation. Surgery may
be planned up to 1 month from the carbon injection.
Needle obstruction by the charcoal powder may occur
but it can be remedied. The probability of failure (i.e., of
not surgically removing the lesion) is about 1 in every
100 procedures [97]. In the cases which do not proceed
to surgical removal of the carbon (e.g., when a benign
diagnosis is obtained with the biopsy), foreign-body
giant-cell reactions that may mimic malignancy on
mammography and US may occur (about 3 cases for
every 100 carbon localisations which are not surgically
excised) [99]. The method is still used in some centres
but less adopted than wire localisation.
Wire localisation
It is the commonest method worldwide. A 3–15 cm wire,
usually with a terminal hook or pigtail, is inserted
through the skin by the radiologist using a co-axial needle
introducer and anchored to the lesion or nearby through
a 16–21-gauge needle that works as introducer. A vari-
able part of the wire comes out of the skin and is taped
or covered until the patient is transferred to the operating
room and the surgeon removes it together with a variable
amount of breast tissue. Wire localisation is a safe, cost-
effective, and standardised technique which may be
performed under US, mammography/tomosynthesis, or
MRI guidance. It strongly reduces the even low risk of
incorrect localisation associated with use of marking
fluids (carbon suspension or radioactive tracers) that
might distribute along the septa, resulting into impreci-
sion. The main complications are patient discomfort suchle breast lesions
thod; however, needing specific local experience. Surgery up to
h after. If not removed, it can mimic malignancy.
used. Surgery at the same day or the day after. Possible vasovagal
s, wire rupture or migration.
local experience is required. Surgery within 24 h after. Radiation
re (low-dose). Higher cost than wire localisation.
local experience is required. Interval time from procedure to surgery
y longer than with radio-guided localisation. Radiation exposure
se). Higher cost than wire localisation.
y introduced. Specific local experience is required. Surgery up to
h after. Higher cost than radio-guided and radioactive seed localisation.
tic seeds to be completely removed to avoid artefacts in breast magnetic
ce imaging examinations.
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syncope, the latter only in 1% of cases), reported in up to
7–10% of patients and less frequent for US than for
mammography guidance), wire rupture or migration [2,
3, 100–104]. The guidewire should be positioned ideally
at the day of surgery or the day before surgery, an issue
which must be considered for surgical scheduling. This
timing is important to avoid possible infections and wire
migration.
Radio-guided occult lesion localisation
ROLL consists in the injection of 0.2–0.3 mL of human
serum albumin labelled with radioactive technetium
(99mTc) inside the tumour [105]. US, mammography, or
MRI guidance can be used. The radiation dose is that
due to a radioactivity of about 7–10MBq, a dose equiva-
lent to 1–2% of that used for a whole-body bone scintig-
raphy (600MBq) [106]. A scintigraphy scan of the breast
is then obtained to check the correct inoculation of the
tracer by comparison between its position and the local-
isation of the lesion on mammograms and/or US. Dur-
ing the surgery, performed no later than 24 h after the
injection, the tumour is detected by a gamma probe,
used by the surgeon to locate the lesion, guide the re-
moval, and verify the removed specimen and the surgical
bed. Experience is needed because the tracer can be dis-
persed in the ducts and identification of the lesion may
fail. Studies showed a correct positioning of the radio-
tracer in 94.6–99.6% of cases [107, 108], allowing for
tumour excision with negative margins in 92% of cases
[108]. A meta-analysis of four randomised controlled trials
totalling 449 patients [109] showed that accurate localisa-
tion, peri-procedural complications, volume and weight of
the excised occult breast lesion, and reoperation rate after
wire localisation and ROLL were similar; duration of local-
isation and surgical excision was shorter for ROLL. Of
note, an additional radiotracer (carried by micromolecules
instead of macromolecules used for ROLL) can be injected
near to the tumour to be drained in the sentinel node, that
will be identified by the gamma probe and then biopsied
during the surgical intervention removing the primary
tumour (sentinel node and occult lesion localisation,
SNOLL) [108]. However, performances of both proce-
dures may be dependent on local experience and their
cost is higher than that of wire localisation.
Radioactive seed localisation
For this approach, radioactive seeds are positioned inside
the tumour under US, mammography/tomosynthesis, or
MRI guidance. These seeds are small titanium radioactive
125I parts (about 0.5 to 1 × 4 to 5mm), commonly used
for brachytherapy (a modality of radiation therapy that
brings many of these seeds inside the tumour) [110]. One
seed has a radioactivity of about 20–30MBq, a doseequivalent to 3–5% of that used for a whole-body bone
scintigraphy. A meta-analysis of six studies totalling 1611
patients [111] showed an overall complete resection rate
ranging from 73 to 97% (the inferior rate was 90% for
studies including over 300 patients); the risk of seed mi-
gration was lower than 1%, that of failure of seed place-
ment from 0 to 7%. The authors concluded that
radioactive seed localisation of nonpalpable breast lesions
is safe and accurate, with an efficacy similar to that of
ROLL and the advantages of possible longer time between
localisation and surgery allowed, without risk of dispersion
through the ductal tree [112]. A potential for reduction of
excised volume in the case of DCIS has been recently
showed using multiple seeds [113]. Obviously, for ROLL
and radioactive seed localisation, a strict cooperation
between the radiology and nuclear medicine/radio-
therapy departments and the availability of a gamma
probe in the operating room are necessary. According
to local regulations, especially in the case of planned
travel of the patient receiving the seed, an official
signed document containing information on the date
of the procedure and the associated radioactivity level
can be given to the patient.
Magnetic seed localisation
This recent localisation method uses 5 × 1mm paramag-
netic steel and iron oxide cylindrical seed, readily visible on
mammography/tomosynthesis and US, supplied preloaded
into an 18-gauge 20-cm needle. The seed is detectable
using a dedicated magnetic probe. The first published re-
ports [114–116] indicated its potential to be a good alterna-
tive to the other methods being radiation free, and not
requiring a short time between localisation and surgery (up
to 30 days interval). The cost is certainly higher than that of
wire or radioactive localisation techniques. Future large
studies are needed to confirm its use in common clinical
practice. Of note, magnetic seeds need to be completely re-
moved to avoid artefacts in breast MRI examinations.
We emphasise that the current recommended and most
commonly used method is wire localisation. Whether alter-
native approaches may lead to equivalent or even better
results has not been established yet and depends on local
experience. In addition, methods using radioactive tracers
or seeds have the drawback of radiation exposure even
though low doses are used. A meta-analysis from the
Cochrane Database published in 2015 [117], considering
eight randomised controlled trials investigating wire local-
isation, ROLL, and radioactive seed localisation concluded
that there is no clear evidence to support one guided tech-
nique over another. The authors support the continued use
of wire localisation as a safe and tested technique that al-
lows for flexibility in selected cases when faced with exten-
sive microcalcifications.
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marking of the skin directly over the nonpalpable breast
lesion and measurement of the depth of the lesion in the
supine operative position using US (when the lesion is
US-detectable) is of great help to the surgeon. Commu-
nication between the radiologist and the surgeon is also
crucial for choosing the best method for localisation,
considering the surgical approach to be used.
Note H. When the pathological result of a biopsied
nonpalpable lesion requires surgical excision, a
preoperative image-guided localisation is performed
by the radiologist. This will allow the surgeon to
access the lesion accurately and to remove it.
Percutaneous localisation can be performed under
US, mammography/tomosynthesis, and MRI
guidance, whichever is more suitable and cost-
effective for the specific case.Conclusions
Image-guided percutaneous needle biopsy represents a
fundamental technique to characterise the nature of sus-
picious breast abnormalities and has almost completely
replaced the surgical biopsy for both palpable and non-
palpable lesions. Radiologists play a crucial role in the
detection as well as diagnosis and management of breast
disease. Depending on the patient profile and lesion
characteristics, the radiologist will choose the best avail-
able biopsy system from FNS, CNB, or VAB. The choice
will also depend on local experience and availability.
When a lesion is visible on US, this is the preferred
method for biopsy being most accessible, comfortable,
and straightforward compared to other techniques. Minor
pain and bleeding are possible post-biopsy sequelae, but
the risk of severe complications is very low. Radiologic-
pathologic correlation is essential for an accurate and suc-
cessful conclusion of the diagnostic procedure.
Preoperative localisation of nonpalpable lesions amenable
to surgery is available through US, mammography/tomo-
synthesis, or MRI guidance, typically by wire insertion.
Frequently asked questions (FAQs)
1. What is the difference between needle biopsy and
excisional biopsy?
Needle biopsies are percutaneous interventional proce-
dures performed with a needle under the guidance of a
breast imaging modality; depending on the needle size,
local anaesthesia is administered. Excisional biopsy is a
surgical operation aiming at removing the entire lesion
to be analysed by the pathologist; it may be performed
under local or general anaesthesia.2. What is the difference between FNS, CNB and VAB?
FNS is percutaneous lesion sampling, usually per-
formed under US guidance, using the same fine needles
suitable for intramuscular injections or thinner needles,
according to local experience. Once the needle is in the
lesion, multiple cells are collected; the biological material
is prepared as smears on glass slides and examined by
the pathologist for a cytological diagnosis. CNB is a per-
cutaneous procedure that uses a spring-loaded needle
for “true cutting” tissue “cores” providing a histological
tissue diagnosis. VAB performs a task similar to that of
CNB using larger needles, facilitated by a vacuum-
generating device that attracts the tissue towards the
needle, allowing removal of larger amounts of tissue in
comparison to CNB.
3. Is breast needle biopsy a painful procedure?
Minor pain and bruising can occur immediately at the
end of the procedure and up to one or two days. If ne-
cessary, adequate analgesic support can be taken.
4. Is local anaesthesia used during a breast biopsy?
Yes, local anaesthesia is always administered before
core needle biopsy (CNB) or vacuum-assisted biopsy
(VAB). Before FNS, as the procedure for delivering an-
aesthesia is not different from collecting cells, local an-
aesthesia is optional.
5. Is there any risk of dissemination or activation of
cancer cells with image-guided interventional
procedures?
The risk of mechanical displacement of malignant cells
along the biopsy tract can rarely occur and is referred to
as “neoplastic seeding”. It has been reported to happen
in less than 2 cases every 1000 biopsies. It is considered
oncologically irrelevant due the high probability of lack
of viability of the displaced cells and to the possible
addition of adjuvant radiation and pharmacological treat-
ment in the case of breast cancer. In fact, preoperative
needle biopsy does not increase local recurrence rate in
breast cancer patients. In addition, if seeding does occur,
it is mostly seen in the skin, which is detected early and
easily treated, with low clinical importance.
6. Can needle biopsies provoke infections?
A very low risk of infection accounting for 1 case every
1000 procedures does exist, and adherence to sterile
working conditions is important. Infectious complica-
tions are limited to skin or soft tissue and respond well
Bick et al. Insights into Imaging           (2020) 11:12 Page 15 of 18to oral antibiotics. The risk of infection may be higher in
patients with diabetes or compromised immune systems.
7. How much waiting time to get the result of the
needle biopsy?
In some centres, the result can be available very soon after
the procedure. Otherwise, the cytology/pathology report
should be available within 1 or 2 weeks after the procedure.
However, special cases (e.g., when a pathological-radiological
discordance happens, requiring consultation among the
specialists and potential re-reading by the pathologist) may
need longer time to provide results.
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